Prevalence of Anti-Varicella-Zoster Virus Antibodies in French Infants under 15 Months of Age
-
Published:2009-04
Issue:4
Volume:16
Page:484-487
-
ISSN:1556-6811
-
Container-title:Clinical and Vaccine Immunology
-
language:en
-
Short-container-title:Clin Vaccine Immunol
Author:
Pinquier Didier12345, Gagneur Arnaud12345, Balu Laurent12345, Brissaud Olivier12345, Gras Le Guen Christèle12345, Hau-Rainsard Isabelle12345, Mory Olivier12345, Picherot Georges12345, De Pontual Loïc12345, Stephan Jean-Louis12345, Maple Peter12345, Breuer Judith12345, Aubert Marie12345, Caulin Evelyne12345, Sana Claudine12345, Pradat Pierre12345, Soubeyrand Benoît12345, Reinert Philippe12345
Affiliation:
1. Hôpital Charles Nicolle, Pôle Mère-Femme-Enfant, Centre Hospitalier Universitaire Rouen, Rouen 2. CHU Brest, Brest 3. Hôpital Jean Verdier, Bondy 4. CHU Bordeaux, Bordeaux 5. Hôpital Mère-Enfant, Centre d'Investigation Clinique Pédiatrique, CHU Nantes, Nantes
Abstract
ABSTRACT
Varicella is a widespread disease of childhood resulting from primary infection with varicella-zoster virus (VZV). The objective of this study was to determine the kinetics of the decline of maternal anti-VZV antibodies in French infants between birth and the age of 15 months in order to estimate the duration of passively acquired maternal anti-VZV immunoglobulin G (IgG). This prospective multicenter study was conducted between October 2005 and January 2007 in the pediatric wards and/or pediatric emergency units of seven French hospitals scattered throughout the country. The level of anti-VZV IgG antibodies in serum was measured by a time-resolved fluorescence immunoassay (TRFIA) (the threshold considered positive is 150 mIU/ml). A total of 345 infants were included. Seventy-seven percent of mothers reported a history of varicella. A rapid decline in the prevalence of anti-VZV antibodies was observed during the first few months of life, with the mean antibody titer decreasing from 536 mIU/ml at birth and through 1 month to below the 150-mIU/ml threshold at 3 to 4 months. The half-life of passively acquired maternal immunoglobulins was around 6 weeks. Based on a large number of subjects, this study clearly demonstrated, for the first time in France, high levels of passively acquired maternal antibodies during the neonatal period, and it allowed us to estimate the duration of passively acquired maternal anti-VZV IgG in French infants. After 4 to 5 months, infants had very low levels of maternal anti-VZV IgG, below the 150-mIU/ml cutoff of the VZV IgG TRFIA.
Publisher
American Society for Microbiology
Subject
Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy
Reference23 articles.
1. Asano, Y., Y. Hiroishi, N. Itakura, S. Hirose, Y. Kajita, S. Suga, and T. Yazaki. 1988. Placental transfer of IgG subclass-specific antibodies to varicella-zoster virus. J. Med. Virol.26:1-6. 2. Asano, Y., and M. Takahashi. 1978. Studies on neutralization of varicella-zoster virus and serological follow-up of cases of varicella and zoster. Biken J.21:15-23. 3. Bonmarin, I., B. Ndiaye, E. Seringe, and D. Levy-Bruhl. 2005. Épidémiologie de la varicelle en France. Bull. Épidémiol. Hebdom.8:30-31. 4. Coudeville, L., A. Brunot, T. D. Szucs, and B. Dervaux. 2005. The economic value of childhood varicella vaccination in France and Germany. Value Health8:209-222. 5. Coudeville, L., F. Paree, T. Lebrun, and J. Sailly. 1999. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine17:142-151.
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|